US3821382A - 5-nitrofuryl derivatives as antibacterial agents - Google Patents
5-nitrofuryl derivatives as antibacterial agents Download PDFInfo
- Publication number
- US3821382A US3821382A US00283134A US28313472A US3821382A US 3821382 A US3821382 A US 3821382A US 00283134 A US00283134 A US 00283134A US 28313472 A US28313472 A US 28313472A US 3821382 A US3821382 A US 3821382A
- Authority
- US
- United States
- Prior art keywords
- furyl
- nitro
- methyl
- pyrimidin
- pyrazolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- -1 5-nitrofuryl Chemical class 0.000 title description 8
- 239000003242 anti bacterial agent Substances 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims description 20
- 241000124008 Mammalia Species 0.000 claims description 7
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 239000000203 mixture Substances 0.000 abstract description 24
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 3
- ZFLQAWZRKKPJCF-UHFFFAOYSA-N 1,6-dimethyl-3-(5-nitrofuran-2-yl)-5H-pyrazolo[3,4-d]pyrimidin-4-one Chemical group CN1N=C(C2=C1N=C(NC2=O)C)C=2OC(=CC2)[N+](=O)[O-] ZFLQAWZRKKPJCF-UHFFFAOYSA-N 0.000 abstract description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 28
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 238000002844 melting Methods 0.000 description 15
- 230000008018 melting Effects 0.000 description 15
- 239000007787 solid Substances 0.000 description 13
- 125000000217 alkyl group Chemical group 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- 239000008298 dragée Substances 0.000 description 9
- 239000013543 active substance Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000000969 carrier Substances 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
- 239000011368 organic material Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- 235000019759 Maize starch Nutrition 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 230000000249 desinfective effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000001117 sulphuric acid Substances 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 208000019206 urinary tract infection Diseases 0.000 description 3
- PNVPNXKRAUBJGW-UHFFFAOYSA-N (2-chloroacetyl) 2-chloroacetate Chemical compound ClCC(=O)OC(=O)CCl PNVPNXKRAUBJGW-UHFFFAOYSA-N 0.000 description 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 2
- TZYQTWHRLVDYPL-UHFFFAOYSA-N 5h-pyrimidin-4-one Chemical compound O=C1CC=NC=N1 TZYQTWHRLVDYPL-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229920000945 Amylopectin Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- VJDDQSBNUHLBTD-GGWOSOGESA-N [(e)-but-2-enoyl] (e)-but-2-enoate Chemical compound C\C=C\C(=O)OC(=O)\C=C\C VJDDQSBNUHLBTD-GGWOSOGESA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 235000013681 dietary sucrose Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- VJDDQSBNUHLBTD-UHFFFAOYSA-N trans-crotonic acid-anhydride Natural products CC=CC(=O)OC(=O)C=CC VJDDQSBNUHLBTD-UHFFFAOYSA-N 0.000 description 2
- JAUFWTSSYRTLLB-UHFFFAOYSA-N (2-phenylacetyl) 2-phenylacetate Chemical compound C=1C=CC=CC=1CC(=O)OC(=O)CC1=CC=CC=C1 JAUFWTSSYRTLLB-UHFFFAOYSA-N 0.000 description 1
- 150000000183 1,3-benzoxazoles Chemical class 0.000 description 1
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical class C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 1
- WLYIIDKKPCXCLS-UHFFFAOYSA-N 3,4,5-tribromo-2-hydroxy-n-phenylbenzamide Chemical compound OC1=C(Br)C(Br)=C(Br)C=C1C(=O)NC1=CC=CC=C1 WLYIIDKKPCXCLS-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 1
- JPIPRHICKKLMOR-UHFFFAOYSA-N 5-(furan-2-yl)-4-nitro-1h-pyrazole Chemical class [O-][N+](=O)C1=CNN=C1C1=CC=CO1 JPIPRHICKKLMOR-UHFFFAOYSA-N 0.000 description 1
- IRBUATMUMJELLE-UHFFFAOYSA-N 5-amino-3-(5-nitrofuran-2-yl)-1-propylpyrazole-4-carbonitrile Chemical compound NC1=C(C(=NN1CCC)C=1OC(=CC1)[N+](=O)[O-])C#N IRBUATMUMJELLE-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical class NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- JOHUAELJNSBTGS-UHFFFAOYSA-N cyclohexanecarbonyl cyclohexanecarboxylate Chemical compound C1CCCCC1C(=O)OC(=O)C1CCCCC1 JOHUAELJNSBTGS-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- LSACYLWPPQLVSM-UHFFFAOYSA-N isobutyric acid anhydride Chemical compound CC(C)C(=O)OC(=O)C(C)C LSACYLWPPQLVSM-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- AMCPECLBZPXAPB-UHFFFAOYSA-N propane-1,2,3-triol;sodium Chemical compound [Na].OCC(O)CO AMCPECLBZPXAPB-UHFFFAOYSA-N 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical class C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- 229960002597 sulfamerazine Drugs 0.000 description 1
- QPPBRPIAZZHUNT-UHFFFAOYSA-N sulfamerazine Chemical compound CC1=CC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 QPPBRPIAZZHUNT-UHFFFAOYSA-N 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical class NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- KUAZQDVKQLNFPE-UHFFFAOYSA-N thiram Chemical compound CN(C)C(=S)SSC(=S)N(C)C KUAZQDVKQLNFPE-UHFFFAOYSA-N 0.000 description 1
- 229960002447 thiram Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- compositions containing these compounds relate to pharmaceutical and animal feedstuff compositions containing these compounds and to methods for the treatment of mammals suffering from bacterial infections, particularly of urinary tract infections, comprising administering to said mammals an effective amount of such compound.
- the invention also provides methods for protecting organic material susceptible to bacterial attack with an effective amount of a compound according to the invention.
- the present invention relates to compounds of the formula I wherein R, is alkyl having from one to fivecarbon atoms or carbalkoxy having from one to five carbon atoms in the alkyl moiety, and
- R is hydrogen, alkyl having from one to five carbon atoms which may be unsubstituted or substituted partially or completely by chloro or bromo; cycloalkyl having from five to seven carbon atoms in the carbocyclic ring, aralkyl having up to 12 carbon atoms, or alkenyl having from two to four carbon atoms.
- alkyl groups having from one to five carbon atoms are methyl, ethyl, n-propyl, isopropyl, nbutyl, tertiarybutyl, and n-pentyl groups.
- R is hydrogen, alkyl having from one to five carbon atoms which may be unsubstituted or substituted partially or completely by chloro or bromo; cycloalkyl having from five to seven carbon atoms in the carbocyclic ring, aralkyl having up to 12 carbon atoms, or alkenyl having from two to four carbon atoms.
- alkyl group contains from one to three carbon atoms.
- Cycloalkyl of from five to seven carbon atoms embraces cyclopentyl, cyclohexyl and cycloheptyl groups, whereby the cyclohexyl group is preferred.
- aralkyl is meant for example the benzyl group and other groups consisting of an aryl and an alkyl moiety, such as phenylethyl, naphthylmethyl and the like.
- Alkenyl containing from two to four carbon atoms embraces the vinyl, ally], 2-methallyl, but 2-enyl and but- 3-enyl group.
- This reaction may be carried out directly between the compound II and the selected reagent, or may be carried out in the presence of aninezrt solvent, such as for example dimethylsulphoxide or dimethylformamide.
- aninezrt solvent such as for example dimethylsulphoxide or dimethylformamide.
- the presence of an inert solvent is of course desirable if the compound II is a solid. In all cases, the reaction willpreferably be carried out at a temperature of from C. to the reflux temperature of the reaction mixture.
- a compound of the general formula II Y may be reacted with a carboxylic acid derivative R COX or (R CO) O where R is as previously defined and X is hydroxyl, halogen (preferably chlorine or bromine), amino, or the grouping -OR where R is an alkyl or alkenyl group containing from one to three carbon atoms, to give an intermediate of formula IV ll il wherein R and R are as previously defined.
- R is an alkyl or alkenyl group containing from one to three carbon atoms
- compounds of general formula wherein R is as herein defined may be reacted with fonnic acid or with carboxylic acid derivative R COX or (R CO) O, where R R and X have their previous significance [except that X may not be hydroxyl] to give an intermediate of general formula VI the reaction being carried out in the presence of an acid or basic catalyst and the intermediate then isolated or immediately cyclised without isolation.
- R COX or (R CO) O where R R and X have their previous significance [except that X may not be hydroxyl]
- the starting compounds of formula Il can be prepared by hydrolysing the corresponding nitrofurylpyrazole derivative having the formulae V wherein R has the previous significance.
- the compounds of formula V are themselves prepared by reacting the corresponding nitrofuryl-nitrilimine which in one of its canonical forms may be represented by the formula X with malononitrile, where R, has its previous significance.
- nitrofuryl-nitrilimine of the formula X may conveniently be generated, as required, during the course of the reaction with malomonitrile, by treating with a base the corresponding nitrofuryl-a-halo-hydrazone having the formula Xl OzNl fl-0-halogen O l
- Their antibacterial activity is demonstrated in a number of conventional pharmacological tests.
- the active compounds are administered in dosages depending on the kind of infection, the species and the age, weight and particular condition of the individual being treated. In general the daily dosage upon oral application will vary from about 1 to 100 mg/kg for mammals.
- the compounds may also be used to protect a high molecular weight hydrophobic or other organic material susceptible to bacterial detenoniation by contacting the organic material with, impregnating in or otherwise treating with, the compounds in amounts up to about 5% by weight.
- the compounds also find application as growth-promoting additives to animal feedstuffs, to which they may be added in proportion of from 5 to 500 parts per million.
- the invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising an antibacterially effective proportion of an active compound of the invention and a pharmacologically acceptable solid carrier or liquid diluent.
- compositions according to the invention contain at least one active compound of the invention as active substance together with a conventional pharmaceutical carrier.
- a conventional pharmaceutical carrier for external use, for example in disinfecting healthy skin, disinfecting wounds and in treating dermatoses and affections of the mucous membranes caused by bacteria, ointments, powders and tinctures are used in particular.
- the ointment bases may be anhydrous, for instance they can consist of mixtures of wool fat and soft paraffin, or they can consist of aqueous emulsions in which the active substance is suspended.
- Suitable carriers for powders are, for instance, rice starch and other starches; the bulk weight of the carriers may be made lighter, if desired, for example by adding highly dispersed silicic acid, or may be made heavier by adding talcum.
- the tinctures may contain at least one active ingredient in aqueous ethanol, in particular 45% to ethanol, to which 10% to 20% of glycerol may be added, if desired. Solutions prepared from polyethylene glycol and other conventional solubility promoters, and also, optionally, from emulsifying agents, maybe used with particular advantage in disinfecting healthy skin.
- the content of active ingredient in pharmaceutical compositions for external application is preferably in the range of from 0.1% to 5%.
- Gargles or concentrates for their preparation, and tablets for slow dissolution in the mouth are suitable for the disinfection of the mouth and throat.
- the former are preferably prepared from alcoholic solutions containing 1% to 5% of active substance to which glycerol or flavourings may be added.
- Lozenges that is solid dosage units, preferably have a relatively high content of sugar or similar substances and a relatively low content of active substance, for instance 0.2% to 20% by weight, as well as the usual convential additives such as binding agents and flavourings.
- Solid dosage units in particular tablets, dragees (sugar coated tablets) and capsules, are convenient for use in intestinal disinfection and for the oral treatment of urinary tract infections. These units preferably contain from to 90% of the active compound to enable the administration of daily doses of from 0.1 to 2.5 grams to adults, or of suitable reduced doses to children to be made. Tablets and dragee cores are produced by combining the active compounds with solid, pulverulent carriers such as lactose, saccharose, sorbitol, maize starch, potato starch or amylopectin, cellulose derivatives or gelatines, preferably with the addition of lubricants such as magnesium or calcium stearate or polyethylene" glycols of suitable molecular weight.
- solid, pulverulent carriers such as lactose, saccharose, sorbitol, maize starch, potato starch or amylopectin, cellulose derivatives or gelatines, preferably with the addition of lubricants such as magnesium or calcium stearate or
- Dragee cores may then be coated, for example with concentrated sugar solutions which can also contain gum arabic, talcum and/or titanium dioxide, or they may be coated with a lacquer dissolved in volatile organic solvents or mixture of solvents.
- Dyestuffs can be added to these coatings, for instance to differentiate between varying dosages.
- Soft gelatine capsules and other closed capsules consist, for example, of a mixture of gelatines and glycerol and may contain, for example, mixtures of the active compound with polyethylene glycol.
- Hard gelatine capsules contain, for example, granulates of an active substance with solid pulverulent carriers, for instance lactose, saccharose, sorbitol, mannitol, starches (such as potato starch, maize starch or amylopectin), cellulose derivatives of. gelatines, and magnesium stearate or stearic acid.
- solid pulverulent carriers for instance lactose, saccharose, sorbitol, mannitol, starches (such as potato starch, maize starch or amylopectin), cellulose derivatives of. gelatines, and magnesium stearate or stearic acid.
- the active compounds can be present as solo active ingredients or they can also be combined with other known pharmacologically active, and especially antibacterial and/or antimycotically active substances, for example to broaden the range of application. They can be combined for example, with 5, 7-dichloro-2-methyl-S-quinolinol or other derivatives of 8-quinolinol, with sulfamerazine or sulfafurazole or other derivatives of sulfanilamide, with chloramphenicol or tetracycline or other antibiotics, with 3,4,5-tribromosalicylanilide or other halogenated salicylanilides, with halogenated carbanilides, with halogenated benzoxazoles or benzoxazolones, with polychloro-hydroxy-diphenylmethanes, with halogendihydroxy-diphenyl sulphides, with 4,4'-dichloro-2- hydroxydiphenylether or 2 ',4,4
- the invention also provides a method of protecting an organic material susceptible to bacterial attack
- EXAMPLE 1 A mixture of 10 grams of 5-amino-4-cyano- 1 -methyl- 3-(5-nitro'2-furyl)-pyrazole and 100 millilitres of 90% formic acid was heated under reflux for 1 hour and cooled. The crystalline solid was collected, washed with water and recrystallised from dimethylformamide. The product was 1-methyl-3-(5-nitro-2-furyl)-lH- pyrazol0[3,4-d]pyrimidin-4(5l-l)-one, having melting point 300 C.
- Example 2 The procedure described in Example 1 was carried out using 5-amino-4-carbamoyl- 1 ,-methyl -3-( 5-nitro-2- furyl)-pyrazole as starting material instead of S-amino- 4-cyanol -methyl-3-( 5 -nitro-2-furyl )-pyrazole, the reaction conditions being the same,
- the product was l-methyl-3-(5-nitro2-furyl)-lH- pyrazolo[3,4-d]pyrimidin-4(5l-ll)-one, having melting which comprises treating the material with an active compound of the invention.
- the organic material may be, for instance, a natural or synthetic polymeric material, a proteinaceous or carbohydrate substance, or a natural or synthetic fibre or textile material formed therefrom.
- EXAMPLE 3 The procedure described in Example 1 was carried out using 5-amino-4-cyanol -isopropyl-3-( 5-nitro-2- furyl)-pyrazole as starting material instead of 5-amino- 4-cyanol -methyl-3-( 5-nitro-2furyl )-pyrazole, the reaction conditions being the same.
- the product was l-isopropyl-3-((5-nitro-2-furyl)-lH- pyrazolo[3,4-d]pyrimidin-4(5H)-one.
- Example 5 The procedure described in Example 1 was carried out using 5-amino-4-cyano-3-( 5-nitro-2-furyl)- l -npentyl-pyrazole as starting material instead of S-amino- 4-cyanol-methyl-3-( 5-nitro-2-furyl )-pyrazole, the reaction conditions being the same.
- the product was 1-methyl-6-(1-propenyl)-3-(5- nitro-2-furyl l H-pyrazolo 3,4-d1pyrimidin-4- (H)-one, which has melting point 300 C.
- the product was 6-chloromethyl-1-methyl-3-(5- nitro-2-furyl 1 H-pyrazolo[ 3 ,4-d]pyrimidin-4 (5l-l)-one, which has melting point 300 C. with decomposition.
- Example 6 The procedure described in Example 6 was carried out using cyclohexane carboxylic anhydride as staring material instead of acetic anhydride, the reaction conditions being the same.
- the product was 6-cyclohexyll-methyl-3-(5-nitro-2- furyl l H-pyrazolo[ 3 ,4-d]pyrimidin-4-( 5 H )-one, which has melting point 300 C.
- the product was 6-benzyl-l-methyl-3-(5-nitro-2- furyl)-1 H-pyrazolo[3 ,4-d pyrimidin-4( 5 H )-one, which has melting point 300 C.
- EXAMPLE 1 1 EXAMPLE 12 The procedure described in Example 1 1 was carried out using crotonic anhydride as starting material instead of propionic anhydride, the reaction conditions being the same.
- the product was 1-methyl-3-(5-nitro-2-furyl)-6-(1- propenyl)-1 H-pyrazolo[3,4-d]pyrimidin- (5 H)-one, having melting point 300C.
- the product was l-methy1-3-(5-nitro-2-furyl)-6- propyl-1l-l-pyrazolo[3,4-d]pyrimidin-4(5H)-one, having melting point 300 C.
- EXAMPLE 15 EXAMPLE 16 The procedure described in Example 1 1 was carried out using chloroacetic anhydride as starting material instead of propionic anhydride, the reaction conditions being otherwise essentially the same.
- the product was 6-chloromethyl-l-methyl-3-(5-nitro-2-furyl)-1H- pyrazolo[3,4-d]pyrimidin-4(5H)-one, having melting point 300 C. with decomposition.
- EXAMPLE 17 A mixture of 2.3 grams of 5-amino-4-cyano-l-.
- methyl-3-(5-nitro-2-furyl)-pyrazole 15 millilitres of dimethylformamide, 15 millilitres of anhydrous pyridine and 0.8 grams of acetyl chloride was heated under reflux for 2 hours and cooled. The mixture was diluted with 50 millilitres of ice-water and the solid which precipitated was collected, washed with water and dried. Recrystallisation from aqueous dimethylformamide gave 5-acetamido-4-cyanol -methyl-3-( 5 nitro-2- furyl)-pyrazole having melting point 250 C.
- EXAMPLE 18 a The procedure described in Example 17 was caracid gave 6-cyclohexyl-l-methyl-3-(5-nitro-2-furyl)-" 1l-l-pyrazolo[3,4-d]pyrimidin-4(4H)-one, having melting point 300 C.
- EXAMPLE 19 A mixture of 11.6 grams of -amino-4-cyano-lmethyl-3-(S-nitro-Z-furyl)-pyrazole, 7.7 grams of phenylacetyl chloride, 50 millilitres of dimethylformamide and 30 millilitres of anhydrous pyridine was heated under reflux for 4 hours and cooled. The mixture was then diluted with 100 millilitres of ice-water and a crude solid was obtained. A mixture of this solid with millilitres of dimethylforrnamide and 10 millilitres of concentrated sulphuric acid (8.0. 1.84) was heated under reflux for 30 minutes and cooled.
- EXAMPLE 20 The procedure described in Example 15 was carried out using 5-amino-4-cyano-l-n-propyl-3-(5-nitro-2- furyl)-pyrazole as starting material instead of S-amino- 4-cyano- 1 -ethoxycarbonyl-3-( 5-nitro-2-furyl pyrazole.
- the product was 6-methyl-1-n-propyl-3-(5-nitro-2- furyl l H-pyrazole[ 3,4-d]pyrimidin-4(5H )-one, having melting point 276 C.
- EXAMPLE 2 PREPARATION OF TABLETS substance. If desired, the tablets can be grooved for better adaption of the dosage.
- composition I is granulated in the heat with composition I through a sieve of 1.2 mmmesh diameter.
- composition 11 is mixed'with composition 11] and the resulting mixture is pressed into 1,000 dragee cores. These are then coated with composition IV and dried. The dragees obtained weigh 255.0 mg and contain 100 mg of active substance.
- the p-hydroxybenzoic acid esters, the citric acid and the sodium cyclarnate are dissolved in the given amount of boiling distilled water, the glycerol is then added to this solution (II).
- the sodium carboxymethyl cellulose and the sugar are thoroughly mixed (Ill).
- Composition III is then added at C to Solution 11 under stirring until complete dissolution of Ill.
- the viscous, slightly turbid liquid is cooled to room temperawherein R, is alkyl having from one to five carbon atoms or carbalkoxy having from one to five carbon atoms in the alkyl moiety; and R is hydrogen, alkyl having from one to five carbon atoms which may be unsubstituted or substituted by chloro or bromo, cycloalkyl having from five to seven carbon atoms in the carbocyclic ring, benzyl, phenylethyl, naphthylmethyl, or alkenyl having from two to four carbon atoms and an inert pharmaceutical carrier.
- a method for the treatment of a mammal suffering from a bacterial infection which method comprises administering to said mammal an antibacterially effective amount of a compound according to claim 1.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compounds of the class of 3-(5-nitro-2-furyl)-1H-pyrazolo(3,4d)pyrimidin-4(5H)-one have antibacterial properties and are active ingredients in pharmaceutical compositions and animal feedstuff compositions, an illustrative example is 1,6-dimethyl3-(5-nitro-2-furyl)-1H-pyrazolo(3,4-d)pyrimidin-4(5H)-one.
Description
United States Patent [191 Hoyle et al.
[111 3,821,382 [4 June 28, 1974 [541 S-NITROFURYL DERIVATIVES As ANTIBACTERIAL AGENTS [75] Inventors: William Hoyle; Graham Arton Y Howarth, both of Cheshire, England [73] Assignee: Ciba-Geigy Corporation, Ardsley,
[22] Filed: Aug. 23, 1972 [21] Appl. No.: 283,134
Related US. Application Data [62] Division of Ser. No. 84,531, Oct. 27, 1970.
[30] Foreign Application Priority Data Oct. 28, 1969 Great Britain 5266 3/69 [52] U.S. C1. 424/251 [51] Int. Cl A6lk 27/00 [58] Field of Search 424/251, 84, 531
[56] References Cited UNITED STATES [PATENTS 3,211,731 10/1965 Schmidt et al 260/2564 3,335,141 8/1967 Burch 260/2564 3,350,397 10/1967 Burch 260/2475 Primary Examiner-Jerome D. Goldberg Attorney, Agent, or Firm-Joseph G. Kolodny; Ronald A. Daignault 2 Claims, No Drawings DETAILED DESCRIPTION The present invention relates'to nitrofuryl derivatives, in particular, to derivatives of 3-(5-nitro-2-furyl)- l l-l-pyrazolo[ 3,4,-d]pyrimidin-4( SI-U-one which compounds have antibacterial properties. It further relates to pharmaceutical and animal feedstuff compositions containing these compounds and to methods for the treatment of mammals suffering from bacterial infections, particularly of urinary tract infections, comprising administering to said mammals an effective amount of such compound. The invention also provides methods for protecting organic material susceptible to bacterial attack with an effective amount of a compound according to the invention.
More particularly, the present invention relates to compounds of the formula I wherein R, is alkyl having from one to fivecarbon atoms or carbalkoxy having from one to five carbon atoms in the alkyl moiety, and
R is hydrogen, alkyl having from one to five carbon atoms which may be unsubstituted or substituted partially or completely by chloro or bromo; cycloalkyl having from five to seven carbon atoms in the carbocyclic ring, aralkyl having up to 12 carbon atoms, or alkenyl having from two to four carbon atoms. Examples of alkyl groups having from one to five carbon atoms are methyl, ethyl, n-propyl, isopropyl, nbutyl, tertiarybutyl, and n-pentyl groups. Preferably, R,
as an alkyl group contains from one to three carbon atoms. Cycloalkyl of from five to seven carbon atoms embraces cyclopentyl, cyclohexyl and cycloheptyl groups, whereby the cyclohexyl group is preferred. By the term aralkyl is meant for example the benzyl group and other groups consisting of an aryl and an alkyl moiety, such as phenylethyl, naphthylmethyl and the like. Alkenyl containing from two to four carbon atoms embraces the vinyl, ally], 2-methallyl, but 2-enyl and but- 3-enyl group.
Compounds of formula I are produced by treating a compound of the formula II B (II) in which R, has the meaning as given under formula I, with a reagent R 'C(OR where R, is an alkyl group containing from one to three carbon atoms, with or 5 without a reaction promotor such as a carboxylic acid anhydride, to give an intermediate of formula III 1 (III wherein R R and R are as herein before defined, which is cyclised without isolation.
This reaction may be carried out directly between the compound II and the selected reagent, or may be carried out in the presence of aninezrt solvent, such as for example dimethylsulphoxide or dimethylformamide. The presence of an inert solvent is of course desirable if the compound II is a solid. In all cases, the reaction willpreferably be carried out at a temperature of from C. to the reflux temperature of the reaction mixture. Alternatively, a compound of the general formula II Y may be reacted with a carboxylic acid derivative R COX or (R CO) O where R is as previously defined and X is hydroxyl, halogen (preferably chlorine or bromine), amino, or the grouping -OR where R is an alkyl or alkenyl group containing from one to three carbon atoms, to give an intermediate of formula IV ll il wherein R and R are as previously defined. The compounds of formula IV are cyclised without isolation.
In a further process, compounds of general formula wherein R is as herein defined, may be reacted with fonnic acid or with carboxylic acid derivative R COX or (R CO) O, where R R and X have their previous significance [except that X may not be hydroxyl] to give an intermediate of general formula VI the reaction being carried out in the presence of an acid or basic catalyst and the intermediate then isolated or immediately cyclised without isolation. Compounds of general formula VI are novel per se, and have antimicrobial activity.
The starting compounds of formula Il can be prepared by hydrolysing the corresponding nitrofurylpyrazole derivative having the formulae V wherein R has the previous significance. The compounds of formula V are themselves prepared by reacting the corresponding nitrofuryl-nitrilimine which in one of its canonical forms may be represented by the formula X with malononitrile, where R, has its previous significance.
The nitrofuryl-nitrilimine of the formula X may conveniently be generated, as required, during the course of the reaction with malomonitrile, by treating with a base the corresponding nitrofuryl-a-halo-hydrazone having the formula Xl OzNl fl-0-halogen O l Their antibacterial activity is demonstrated in a number of conventional pharmacological tests. Thus it is shown that, for example, l-methyl-3-( 5-nitro-2-furyl)- 1H-pyrazolo[3,4-d]pyrimidin-4(5l-l)-one and 1,6- dimethyl-3-(5-nitro-2-furyl)-1H-pyrazolo[3 ,4- d]pyrimidin-4(5H)-one have in vitro an excellent growth inhibiting effect against staphylococcus aureus, Escherichia coli, Klebsiella pneumonia, Salmonella typhi and others if added in amounts of about 1 to about 10 y/ml to the bacterial culture.
The toxicity of the compounds of the invention as demonstrated for example in mice is of favourable low order.
For their intended internal use, for example for the treatment of intestinal and urinary tract infections, the active compounds are administered in dosages depending on the kind of infection, the species and the age, weight and particular condition of the individual being treated. In general the daily dosage upon oral application will vary from about 1 to 100 mg/kg for mammals. The compounds may also be used to protect a high molecular weight hydrophobic or other organic material susceptible to bacterial detenoniation by contacting the organic material with, impregnating in or otherwise treating with, the compounds in amounts up to about 5% by weight. The compounds also find application as growth-promoting additives to animal feedstuffs, to which they may be added in proportion of from 5 to 500 parts per million.
Accordingly, the invention also provides a pharmaceutical composition comprising an antibacterially effective proportion of an active compound of the invention and a pharmacologically acceptable solid carrier or liquid diluent.
The pharmaceutical compositions according to the invention contain at least one active compound of the invention as active substance together with a conventional pharmaceutical carrier. The type of carrier actually used depends to a great extent on the intended application; for external use, for example in disinfecting healthy skin, disinfecting wounds and in treating dermatoses and affections of the mucous membranes caused by bacteria, ointments, powders and tinctures are used in particular. The ointment bases may be anhydrous, for instance they can consist of mixtures of wool fat and soft paraffin, or they can consist of aqueous emulsions in which the active substance is suspended. Suitable carriers for powders are, for instance, rice starch and other starches; the bulk weight of the carriers may be made lighter, if desired, for example by adding highly dispersed silicic acid, or may be made heavier by adding talcum. The tinctures may contain at least one active ingredient in aqueous ethanol, in particular 45% to ethanol, to which 10% to 20% of glycerol may be added, if desired. Solutions prepared from polyethylene glycol and other conventional solubility promoters, and also, optionally, from emulsifying agents, maybe used with particular advantage in disinfecting healthy skin. The content of active ingredient in pharmaceutical compositions for external application is preferably in the range of from 0.1% to 5%.
Gargles or concentrates for their preparation, and tablets for slow dissolution in the mouth, are suitable for the disinfection of the mouth and throat. The former are preferably prepared from alcoholic solutions containing 1% to 5% of active substance to which glycerol or flavourings may be added. Lozenges, that is solid dosage units, preferably have a relatively high content of sugar or similar substances and a relatively low content of active substance, for instance 0.2% to 20% by weight, as well as the usual convential additives such as binding agents and flavourings.
Solid dosage units, in particular tablets, dragees (sugar coated tablets) and capsules, are convenient for use in intestinal disinfection and for the oral treatment of urinary tract infections. These units preferably contain from to 90% of the active compound to enable the administration of daily doses of from 0.1 to 2.5 grams to adults, or of suitable reduced doses to children to be made. Tablets and dragee cores are produced by combining the active compounds with solid, pulverulent carriers such as lactose, saccharose, sorbitol, maize starch, potato starch or amylopectin, cellulose derivatives or gelatines, preferably with the addition of lubricants such as magnesium or calcium stearate or polyethylene" glycols of suitable molecular weight. Dragee cores may then be coated, for example with concentrated sugar solutions which can also contain gum arabic, talcum and/or titanium dioxide, or they may be coated with a lacquer dissolved in volatile organic solvents or mixture of solvents. Dyestuffs can be added to these coatings, for instance to differentiate between varying dosages. Soft gelatine capsules and other closed capsules consist, for example, of a mixture of gelatines and glycerol and may contain, for example, mixtures of the active compound with polyethylene glycol. Hard gelatine capsules contain, for example, granulates of an active substance with solid pulverulent carriers, for instance lactose, saccharose, sorbitol, mannitol, starches (such as potato starch, maize starch or amylopectin), cellulose derivatives of. gelatines, and magnesium stearate or stearic acid.
In all forms for administration the active compounds can be present as solo active ingredients or they can also be combined with other known pharmacologically active, and especially antibacterial and/or antimycotically active substances, for example to broaden the range of application. They can be combined for example, with 5, 7-dichloro-2-methyl-S-quinolinol or other derivatives of 8-quinolinol, with sulfamerazine or sulfafurazole or other derivatives of sulfanilamide, with chloramphenicol or tetracycline or other antibiotics, with 3,4,5-tribromosalicylanilide or other halogenated salicylanilides, with halogenated carbanilides, with halogenated benzoxazoles or benzoxazolones, with polychloro-hydroxy-diphenylmethanes, with halogendihydroxy-diphenyl sulphides, with 4,4'-dichloro-2- hydroxydiphenylether or 2 ',4,4 '-trichloro-2-hydroxydiphenylether or other polyhalogenhydroxydiphenylethers, or with bactericidal quaternary compounds or with certain dithiocarbamic acid derivatives such as tetramethylthiuram disulphide. Also, carriers which themselves have favourable pharmacological properties may be used, for instance sulphur as a powder base or zine stearate as a component of ointment bases.
The invention also provides a method of protecting an organic material susceptible to bacterial attack EXAMPLE 1 A mixture of 10 grams of 5-amino-4-cyano- 1 -methyl- 3-(5-nitro'2-furyl)-pyrazole and 100 millilitres of 90% formic acid was heated under reflux for 1 hour and cooled. The crystalline solid was collected, washed with water and recrystallised from dimethylformamide. The product was 1-methyl-3-(5-nitro-2-furyl)-lH- pyrazol0[3,4-d]pyrimidin-4(5l-l)-one, having melting point 300 C.
EXAMPLE 2 The procedure described in Example 1 was carried out using 5-amino-4-carbamoyl- 1 ,-methyl -3-( 5-nitro-2- furyl)-pyrazole as starting material instead of S-amino- 4-cyanol -methyl-3-( 5 -nitro-2-furyl )-pyrazole, the reaction conditions being the same,
The product was l-methyl-3-(5-nitro2-furyl)-lH- pyrazolo[3,4-d]pyrimidin-4(5l-ll)-one, having melting which comprises treating the material with an active compound of the invention. The organic material may be, for instance, a natural or synthetic polymeric material, a proteinaceous or carbohydrate substance, or a natural or synthetic fibre or textile material formed therefrom.
point 300 C., identical with the product obtained in Example l.
EXAMPLE 3 EXAMPLE 4 The procedure described in Example 1 was carried out using 5-amino-4-cyanol -isopropyl-3-( 5-nitro-2- furyl)-pyrazole as starting material instead of 5-amino- 4-cyanol -methyl-3-( 5-nitro-2furyl )-pyrazole, the reaction conditions being the same.
The product was l-isopropyl-3-((5-nitro-2-furyl)-lH- pyrazolo[3,4-d]pyrimidin-4(5H)-one.
EXAMPLE 5 The procedure described in Example 1 was carried out using 5-amino-4-cyano-3-( 5-nitro-2-furyl)- l -npentyl-pyrazole as starting material instead of S-amino- 4-cyanol-methyl-3-( 5-nitro-2-furyl )-pyrazole, the reaction conditions being the same.
The product was 3-(5-nitro-2-furyl)-l-n-pentyl-lH- pyrazolo[ 3 ,4-d ]pyrimidin-4( 5H )-o ne.
EXAMPLE 6 A mixture of 10 grams of 5-amino-4-carbamoyllmethyl-3-(5-nitro-2-furyl)-pyrazole and millilitres of acetic anhydride was heated under reflux for 6 hours and cooled. The crystalline solid was collected, washed with alcohol and recrystallised from dimethylformamide.
EXAMPLE 7 The procedure described in Example 6 was carried out using crotonic anhydride as starting material instead of acetic anhydride, the reaction conditions being the same.
The product was 1-methyl-6-(1-propenyl)-3-(5- nitro-2-furyl l H-pyrazolo 3,4-d1pyrimidin-4- (H)-one, which has melting point 300 C.
EXAMPLE 8 The procedure described in Example 6 was carried outusing chloro-acetic anhydride as starting material instead of acetic anhydride, the reaction conditions being the same.
The product was 6-chloromethyl-1-methyl-3-(5- nitro-2-furyl 1 H-pyrazolo[ 3 ,4-d]pyrimidin-4 (5l-l)-one, which has melting point 300 C. with decomposition.
EXAMPLE 9,
The procedure described in Example 6 was carried out using cyclohexane carboxylic anhydride as staring material instead of acetic anhydride, the reaction conditions being the same.
The product was 6-cyclohexyll-methyl-3-(5-nitro-2- furyl l H-pyrazolo[ 3 ,4-d]pyrimidin-4-( 5 H )-one, which has melting point 300 C.
EXAMPLE 10 The procedure described in Example 6 was carried out using phenylacetic anhydride as starting material instead of acetic anhydride, the reaction conditions being the same.
The product was 6-benzyl-l-methyl-3-(5-nitro-2- furyl)-1 H-pyrazolo[3 ,4-d pyrimidin-4( 5 H )-one, which has melting point 300 C.
EXAMPLE 1 1 EXAMPLE 12 The procedure described in Example 1 1 was carried out using crotonic anhydride as starting material instead of propionic anhydride, the reaction conditions being the same.
The product was 1-methyl-3-(5-nitro-2-furyl)-6-(1- propenyl)-1 H-pyrazolo[3,4-d]pyrimidin- (5 H)-one, having melting point 300C.
EXAMPLE 13 The procedure described in Example 1 1 was carried out using butyric anhydride as starting material instead of propionic anhydride, the reaction conditions being the same.
The product was l-methy1-3-(5-nitro-2-furyl)-6- propyl-1l-l-pyrazolo[3,4-d]pyrimidin-4(5H)-one, having melting point 300 C.
EXAMPLE 14 A mixture of 14.0 grams of 5-amino-4-cyano-lmethyl-3-(5-nitro-2-furyl)-pyrazole, 9.5 grams isobutyric anhydride and 0.6 grams of concentrated sulphuric acid (8.6. 1.84) was heated at a reaction temperature of l00120 C. for 15 minutes and then cooled. The solid which crystallised was collected, washed with ether and dried. Recrystallisation from aqueous dimethylformamide gave 4-cyano-5- isobutyramido- 1 -methyl-3-( 5 -nitro-2-furyl )-pyrazole having melting point 225 C. r
A mixture of 3.5 grams of 4-cyano-5-isobutyr-amido- 1-methyl-3-(5-nitro-2-furyl)-pyrazole, 20 millilitres of dimethylformamide and 10 millilitres of concentrated sulphuric acid (SC. 1.84) was heated under relfux for 1 hour and cooled. The mixture was then diluted with 50 millilitres of water and the solid which formed was collected, washed with water and dried. Recrystallisation from dimethylformamide gave 6-isopropyl-1- methyl-3-( 5-nitro-2-furyl 1 l-l-pyrazolo[ 3 ,4- d]pyrimidin-4(5l-l)-one, having melting point 300 C.
EXAMPLE 15 EXAMPLE 16 The procedure described in Example 1 1 was carried out using chloroacetic anhydride as starting material instead of propionic anhydride, the reaction conditions being otherwise essentially the same. The product was 6-chloromethyl-l-methyl-3-(5-nitro-2-furyl)-1H- pyrazolo[3,4-d]pyrimidin-4(5H)-one, having melting point 300 C. with decomposition.
EXAMPLE 17 A mixture of 2.3 grams of 5-amino-4-cyano-l-.
methyl-3-(5-nitro-2-furyl)-pyrazole, 15 millilitres of dimethylformamide, 15 millilitres of anhydrous pyridine and 0.8 grams of acetyl chloride was heated under reflux for 2 hours and cooled. The mixture was diluted with 50 millilitres of ice-water and the solid which precipitated was collected, washed with water and dried. Recrystallisation from aqueous dimethylformamide gave 5-acetamido-4-cyanol -methyl-3-( 5 nitro-2- furyl)-pyrazole having melting point 250 C.
EXAMPLE 18 a. The procedure described in Example 17 was caracid gave 6-cyclohexyl-l-methyl-3-(5-nitro-2-furyl)-" 1l-l-pyrazolo[3,4-d]pyrimidin-4(4H)-one, having melting point 300 C.
EXAMPLE 19 A mixture of 11.6 grams of -amino-4-cyano-lmethyl-3-(S-nitro-Z-furyl)-pyrazole, 7.7 grams of phenylacetyl chloride, 50 millilitres of dimethylformamide and 30 millilitres of anhydrous pyridine was heated under reflux for 4 hours and cooled. The mixture was then diluted with 100 millilitres of ice-water and a crude solid was obtained. A mixture of this solid with millilitres of dimethylforrnamide and 10 millilitres of concentrated sulphuric acid (8.0. 1.84) was heated under reflux for 30 minutes and cooled. Dilution of the mixture with 50 millilitres of ice-water yielded a product which on recrystallisation from di' methylformamide gave 6-benzyl-l-methyl-3-(5-nitro 2-furyl)- l H-pyrazolo-[3,4-d]pyrimidin-4-( 5l-l)-one, having melting point 300 C.
EXAMPLE 20 The procedure described in Example 15 was carried out using 5-amino-4-cyano-l-n-propyl-3-(5-nitro-2- furyl)-pyrazole as starting material instead of S-amino- 4-cyano- 1 -ethoxycarbonyl-3-( 5-nitro-2-furyl pyrazole.
The product was 6-methyl-1-n-propyl-3-(5-nitro-2- furyl l H-pyrazole[ 3,4-d]pyrimidin-4(5H )-one, having melting point 276 C.
EXAMPLE 2] PREPARATION OF TABLETS substance. If desired, the tablets can be grooved for better adaption of the dosage.
Example 22 Preparation of Dragees for 1,000 Composition dragees l 1,6-Dimethyl-3-(5- nitroZ-furyD-IH- pyrazolo[3,4-d]pyrimidin- 4(5H)-one 100.0 g
Maize starch 27.0 g
Gelatin 8.0 g
ll Glycerol 2.0 g
Distilled water q.s. ad 100 ml Maize starch 10.0 g 111 Talcu'm I V 7.0 g
Magnesium stearate 1.0 g 155.0 g N White dragee coating Shellac 2.0 g
Sugar 50.0 g Talcum 38.0 g Gum arabic 7.4 g
Colloidal silicon dioxide 22 g Titanium dioxide 0.4 g
Composition I is granulated in the heat with composition I through a sieve of 1.2 mmmesh diameter. The
dried granulate is mixed'with composition 11] and the resulting mixture is pressed into 1,000 dragee cores. These are then coated with composition IV and dried. The dragees obtained weigh 255.0 mg and contain 100 mg of active substance.
EXAMPLE 23 0 Preparation of a Syrup l-Methyl-3-(5-nitro-2-furyl)-1H- pyrazolo[3,4-d]pyrimidin-4( 5H )-one Colloidal silicone dioxide p-Hydroxybenzoic acid methyl ester p-Hydroxybenzoic acid propyl ester Citric acid Sodium cyclamate Distilled water Glycerol Sodium carboxymethyl cellulose Sugar The active substance and the colloidal silicon dioxide are passed through a sieve of 1.2 mm mesh diameter (1). 1
The p-hydroxybenzoic acid esters, the citric acid and the sodium cyclarnate are dissolved in the given amount of boiling distilled water, the glycerol is then added to this solution (II). The sodium carboxymethyl cellulose and the sugar are thoroughly mixed (Ill).
Composition III is then added at C to Solution 11 under stirring until complete dissolution of Ill. The viscous, slightly turbid liquid is cooled to room temperawherein R, is alkyl having from one to five carbon atoms or carbalkoxy having from one to five carbon atoms in the alkyl moiety; and R is hydrogen, alkyl having from one to five carbon atoms which may be unsubstituted or substituted by chloro or bromo, cycloalkyl having from five to seven carbon atoms in the carbocyclic ring, benzyl, phenylethyl, naphthylmethyl, or alkenyl having from two to four carbon atoms and an inert pharmaceutical carrier. 2. A method for the treatment of a mammal suffering from a bacterial infection, which method comprises administering to said mammal an antibacterially effective amount of a compound according to claim 1.
Claims (1)
- 2. A method for the treatment of a mammal suffering from a bacterial infection, which method comprises administering to said mammal an antibacterially effective amount of a compound according to claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US00283134A US3821382A (en) | 1969-10-28 | 1972-08-23 | 5-nitrofuryl derivatives as antibacterial agents |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB5266369 | 1969-10-28 | ||
GB4305670 | 1970-09-09 | ||
GB4305570 | 1970-09-09 | ||
GB4305470 | 1970-09-09 | ||
US8453170A | 1970-10-27 | 1970-10-27 | |
US00283134A US3821382A (en) | 1969-10-28 | 1972-08-23 | 5-nitrofuryl derivatives as antibacterial agents |
Publications (1)
Publication Number | Publication Date |
---|---|
US3821382A true US3821382A (en) | 1974-06-28 |
Family
ID=27546743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US00283134A Expired - Lifetime US3821382A (en) | 1969-10-28 | 1972-08-23 | 5-nitrofuryl derivatives as antibacterial agents |
Country Status (1)
Country | Link |
---|---|
US (1) | US3821382A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050197340A1 (en) * | 2004-02-27 | 2005-09-08 | Nidhi Arora | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same |
US20050203091A1 (en) * | 2004-02-27 | 2005-09-15 | Roche Palo Alto Llc | Heteroaryl-fused pyrazolo derivatives and methods for using the same |
US20070049598A1 (en) * | 2005-08-25 | 2007-03-01 | Roche Palo Alto Llc | p38 Map kinase inhibitors and methods for using the same |
-
1972
- 1972-08-23 US US00283134A patent/US3821382A/en not_active Expired - Lifetime
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050197340A1 (en) * | 2004-02-27 | 2005-09-08 | Nidhi Arora | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same |
US20050203091A1 (en) * | 2004-02-27 | 2005-09-15 | Roche Palo Alto Llc | Heteroaryl-fused pyrazolo derivatives and methods for using the same |
US7435731B2 (en) * | 2004-02-27 | 2008-10-14 | Roche Palo Alto Llc | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same |
US7452880B2 (en) * | 2004-02-27 | 2008-11-18 | Nidhi Arora | Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same |
US20070049598A1 (en) * | 2005-08-25 | 2007-03-01 | Roche Palo Alto Llc | p38 Map kinase inhibitors and methods for using the same |
US7563799B2 (en) | 2005-08-25 | 2009-07-21 | Roche Palo Alto Llc | Substituted pyrazolo[3,4-D]pyrimidines as p38 map kinase inhibitors |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS62161728A (en) | Antibacterial | |
US3755324A (en) | 3-(5-nitro-2-furyl)-1h-pyrazolo{8 3,4{9 pyrimidins-4(5h)-ones | |
US3905971A (en) | 2-Phenyl-as-triazine-3,5(2H,4H)diones | |
US3228833A (en) | Anticoccidial compositions and methods of using same | |
US3769295A (en) | Nitrofuryl derivatives of 5-substituted isoxazolines | |
JPH0140837B2 (en) | ||
US3821382A (en) | 5-nitrofuryl derivatives as antibacterial agents | |
US3948913A (en) | New 5-nitrofuryl derivatives | |
US4044130A (en) | Compositions for the control of microorganisms | |
US3560496A (en) | 2-benzyl-as-triazine-3,5(2h,4h) diones | |
JPS6041656A (en) | Manufacture of novel aminoacid derivative | |
US3906101A (en) | Pharmaceutical compositions containing substituted 5-nitrofurfurylideneamino-oxazolidinones | |
US3632577A (en) | 5-nitrofuryl derivatives | |
US3682956A (en) | Substituted 3-(5-nitro-2-furyl)-pyrazoles | |
US3686170A (en) | Novel substituted t-nitrofurfurylideneamino-oxazolidinones | |
US3835165A (en) | Nitrofuryl-alpha-halo-hydrazones | |
US3026332A (en) | Nitrofurfurylidene hydroxy acid hydrazides | |
US3598812A (en) | 5-nitrofuryl derivatives | |
US3682953A (en) | Substituted 5-nitrofuryl-pyrazoles | |
US3415838A (en) | Nitrogen-containing derivatives of 2,5-dichloro-3-nitrobenzoic acid | |
US3562286A (en) | Nitrofuryl isoxazole derivatives | |
IE44860B1 (en) | 3-(3-(3-hydroxypiperid-2-yl)acetonyl)-3h-quinazolin-4-ones | |
US3793316A (en) | 5-nitrofuryl derivatives | |
US3790615A (en) | O,n-diphenylthiocarbamic acid esters | |
US3407195A (en) | 4-methyl-1-(5-nitrofurfurylideneamino)-2-imidazolidinone |